Please assess the completion status of the following clinical trial:

Trial Title: PREvention of VENous ThromboEmbolism Following Radical Prostatectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men 18-100 years of age with histologically confirmed prostate cancer of any stage undergoing RP~* Patients who would have otherwise been eligible to receive routine post-RP care~Exclusion Criteria:~* Active treatment for VTE~* Patients judged by patients' urologist, primary care doctor, or in the preoperative evaluation center (PEC) to be unsafe to forgo pharmacologic prophylaxis or systemic anticoagulation postoperatively (whether or not patients are on systematic anticoagulation for indications other than VTE)~* Known adverse reactions to heparin (heparin-induced thrombocytopenia or any allergy)~* Epidural analgesia~* Spinal anesthesia~* Participation in a different trial that increases a patient's risk of VTE

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Subcutaneous Heparin (Type: EXPERIMENTAL): Patients randomized to the pharmacologic VTE prophylaxis arm will receive a dose of subcutaneous heparin 5,000 units prior to incision, and subcutaneous heparin 5,000 units every 8 hours after surgery until discharge.
- Control (Type: NO_INTERVENTION): Patients randomized to the control arm will receive routine care with intermittent pneumatic compression devices.

Based on this trial design, predict the completion outcome and termination type (if applicable).